CJC-1295 has no published human RCTs for adult anti-aging, body composition, recovery, or sleep quality. The compound was developed in the early 2000s by ConjuChem Biotechnologies as a modified long-acting GHRH analog — with or without the Drug Affinity Complex (DAC) that binds serum albumin and extends plasma half-life. It was never approved by FDA for any indication and was only ever sold as a research chemical. The GHRH-receptor mechanism class is anchored to Sermorelin (Walker 1994, PMID: 7527273); CJC-1295 shares that receptor, but its own published human efficacy data is absent.
CJC-1295 shares Sermorelin's upstream GHRH-receptor mechanism. The Walker 1994 pharmacodynamic data (PMID: 7527273) on Sermorelin and the Reutens 1996 pediatric-diagnostic programme (PMID: 8834260) establish the receptor class in humans. CJC-1295 itself adds a half-life extension (DAC serum-albumin binding) to that mechanism — pharmacokinetic, not new efficacy data.
Body composition, fat loss, weekly anti-aging, sleep quality, "longevity" — zero published human RCTs for any of these endpoints. All online claims are extrapolated from GHRH-axis pharmacology and post-market reports. No controlled trial has tested these outcomes in healthy adults.
CJC-1295 sits in a peculiar spot in the online peptide-clinic ecosystem: it appears in virtually every Sermorelin + Ipamorelin combination blend, yet it has the thinnest human evidence base of the three. The pharmacokinetic story is genuinely interesting — the DAC variant's serum-albumin binding extends plasma half-life to multi-day exposure, producing the weekly dosing schedule now standard in wellness clinics. Pharmacokinetic convenience is not, however, clinical efficacy.
This page maps what the research actually shows: where CJC-1295's evidence is solid (mechanism-class shared with Sermorelin), where it's preliminary (pharmacokinetic extension of a known mechanism), and where it's extrapolation (body composition, anti-aging, recovery). The half-life distinction between CJC-1295 (DAC) and Sermorelin is real. The empirical gap between any GHRH analog and a body-composition or anti-aging outcome in healthy adults is the same untested question that applies to Sermorelin itself.
What Is CJC-1295?
CJC-1295 is a 30-amino-acid modified analog of growth hormone-releasing hormone (GHRH 1–30) developed by ConjuChem Biotechnologies in the early 2000s. Endogenous GHRH is a 44-amino-acid hypothalamic peptide; CJC-1295 retains the bioactive N-terminal fragment with specific substitutions designed to resist enzymatic degradation and, in the DAC variant, to bind endogenous serum albumin.
The compound was investigated as a long-acting alternative to recombinant GH for adult GH-deficiency replacement. Two variants entered the gray-market research-chemical pipeline: the non-DAC form (a moderately-extended half-life version, often labeled "CJC-1295 without DAC" or "Modified GRF 1-30"), and the DAC form (a serum-albumin-binding conjugate with multi-day plasma exposure). Neither variant ever advanced to a New Drug Application, and neither is FDA-approved for any current indication. CJC-1295 is sold today in the same gray-market research-chemical and 503A-compounding channels as Sermorelin and the GHRPs — never through FDA-approved prescribing channels.
The distinction that matters
The marketing pitch for CJC-1295 rests on the DAC variant's extended half-life: a single weekly injection, rather than Sermorelin's nightly dosing. This is pharmacologically real. The maleimide-linked reactive group on the DAC variant binds cysteine-34 of endogenous serum albumin, dramatically slowing renal clearance and producing sustained plasma exposure. The mechanism is unchanged — same GHRH receptor on pituitary somatotrophs, same endogenous pulse amplification — but the frequency of administration is altered. A pharmacokinetic improvement is not, however, a clinical efficacy improvement. The endpoints CJC-1295 is being marketed for (body composition, fat loss, anti-aging, sleep quality) have not been tested in human RCTs.
The Reutens 1996 data (PMID: 8834260) and the Walker 1994 pharmacodynamic study (PMID: 7527273) establish that Sermorelin analogue compounds reliably elevate GH in humans under controlled conditions — the GHRH-receptor mechanism class is documented for the upstream pathway CJC-1295 inherits. That is a defined, peer-reviewed pharmacological property. It is not a body-composition or anti-aging clinical endpoint.
Mechanism of Action
CJC-1295's mechanism operates through the same GH/IGF-1 axis as Sermorelin and the GHRPs, but at a different step in the cascade and with a different pharmacokinetic profile:
- GHRH-receptor binding — CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, amplifying pulsatile GH release from the same pituitary pool that endogenous GHRH taps. Mechanism is upstream of the ghrelin-receptor pathway used by Ipamorelin, GHRP-6, GHRP-2, and hexarelin, and identical to Sermorelin's receptor target.
- Half-life extension via DAC (Drug Affinity Complex) — the DAC variant adds a maleimide-linked reactive group that binds endogenous serum albumin, extending plasma half-life to multi-day exposure. The non-DAC variant has a moderately extended half-life compared to Sermorelin; both are substantially longer than Sermorelin's short-acting profile. The extension is pharmacokinetic only — the mechanism of action at the receptor is unchanged.
- Pulse amplification, not pulse triggering — because CJC-1295 acts through the natural GHRH receptor rather than the pharmacologically distinct ghrelin (GHSR-1a) receptor, it amplifies existing nocturnal and exercise-induced GH pulses rather than imposing a new pulse rhythm. Community practice assumes the weekly sustained exposure produces a sustained elevation; the controlled pharmacokinetic data does not establish that downstream IGF-1 levels remain in a physiological range across the dosing interval.
- Proposed downstream effects via GH/IGF-1 — muscle protein synthesis support, lipolysis, bone density, and sleep architecture. These are theoretically downstream of GH elevation; the same caveat that applies to Sermorelin and the GHRPs applies here.
Half-life ≠ efficacy. The DAC variant's extended exposure is a real pharmacokinetic improvement — a single weekly injection rather than a nightly one is genuinely more practical. Practical convenience does not establish clinical efficacy for body composition, anti-aging outcomes, or recovery speed in healthy adults. CJC-1295 has the same untested-in-adults question that applies to Sermorelin and the GHRP class.
The Evidence Landscape
| Indication | Evidence Level | Best Study / Citation |
|---|---|---|
| GHRH-receptor pharmacodynamics in healthy adults (mechanism class only) | Established in humans (mechanism class) | Walker BR, et al. J Clin Endocrinol Metab. 1994;79(6):1662–1667. PMID: 7527273 — Sermorelin anchor, shared GHRH receptor with CJC-1295. |
| Body composition in healthy adults (muscle / fat loss) | Not established | No human RCT for body-composition endpoints. Half-life extension is pharmacokinetic; no efficacy translation has been demonstrated. |
| Adult anti-aging / longevity | Not established | No human data. Mechanism class is established; clinical efficacy for anti-aging endpoints is extrapolated from GH-axis pharmacology. |
| Sleep quality / slow-wave sleep | Not established | No controlled human trial. GH peak coupling with slow-wave sleep is well documented in physiology but CJC-1295-induced sleep-quality changes are untested. |
Human Evidence: What Actually Exists
CJC-1295's human evidence base is inherited, not generated. The compound was developed by ConjuChem in the early 2000s and explored as a long-acting GHRH alternative for adult GH-deficiency replacement, but the published peer-reviewed human pharmacodynamic data for CJC-1295 itself is limited. The receptor mechanism class is anchored to Sermorelin's published data.
The Walker 1994 pharmacodynamic anchor (reused): This is the canonical reference for the GHRH-receptor mechanism class that CJC-1295 inherits. Published in the Journal of Clinical Endocrinology & Metabolism (PMID: 7527273), it characterized Sermorelin's effect on endogenous GH pulsatility in healthy adults. The work confirmed that GHRH 1–29 amplification preserves rather than replaces the natural pulse architecture — a real, replicated pharmacological finding that extends to CJC-1295 by virtue of the shared receptor. The mechanism class is established. The efficacy extrapolation to body composition or anti-aging endpoints is not established.
The Reutens 1996 diagnostic-stimulation programme (background-only): The Reutens 1996 study (Clinical Endocrinology, PMID: 8834260) is part of the pediatric GH-deficiency diagnostic-stimulation literature for Sermorelin. CJC-1295 does not have an analogous diagnostic-stimulation history of its own — the ConjuChem research programme pursued the long-acting GHRH analog for adult GH-replacement, not for diagnostic application.
The common misreading: CJC-1295 discussions in anti-aging clinic marketing typically cite the DAC half-life extension as though it expands the therapeutic window. It extends the pharmacokinetic window. It does not generate new efficacy evidence. The mechanism is upstream GHRH-receptor amplification; the duration is longer; the gap from mechanism to body-composition outcome is the same gap that Sermorelin has never closed.
The Vendor Reality
CJC-1295 sold today — through peptide vendors, gray-market research-chemical resellers, and 503A compounding pharmacies in legal gray zones — is not subject to the quality controls that govern FDA-approved drugs. The compound may be:
- Pure and accurately dosed — or contaminated with endotoxins, particulate matter, or mislabeled peptides
- Correctly stored and shipped — the DAC variant's serum-albumin-binding conjugate is more sensitive to temperature excursions than the non-DAC variant, and lyophilized stability differs across the two forms
- Actually CJC-1295 (with or without DAC as labeled) — or a different GHRF, a GHRP, a Sermorelin-labeled blend, or a degraded fragment, since analytical verification is the only way to confirm identity
CJC-1295 is almost never sold as a single-compound vial for anti-aging clinic use. The dominant retail form is a combination blend with Ipamorelin (and sometimes Sermorelin). Combination blends introduce one or two additional compounds — with their own evidence gaps, regulatory status, and WADA exposure — each component requiring independent verification. The CJC-1295 + Ipamorelin blend is the canonical weekly peptide-clinic "anti-aging" prescription in 2026, but the underlying evidence for any specific adult endpoint remains absent on every component.
What to verify before buying CJC-1295: Ask for a Certificate of Analysis (COA) from an independent lab — mass spectrometry for identity confirmation (DAC and non-DAC variants differ by mass), HPLC for purity (>95%), and endotoxin testing. Combination blends (CJC-1295 + Ipamorelin, CJC-1295 + Sermorelin, three-way blends) require independent verification of every peptide in the blend. If a vendor can't or won't provide this documentation, don't buy from them.
Regulatory Status in 2026
FDA status
CJC-1295 is not an FDA-approved drug for any current indication. The early-2000s ConjuChem research programme did not advance to a New Drug Application. CJC-1295 has no current compounding monograph and is not on the FDA bulk drug substances list as an eligible compounding agent. CJC-1295 administered for adult anti-aging, body composition, sleep, or longevity use sits outside any approved regulatory pathway.
WADA prohibition
CJC-1295 is explicitly listed under WADA's S2 category — Peptide Hormones, Growth Factors, Related Substances and Mimetics — specifically under the "GH-Releasing Factors (GHRFs)" subcategory alongside Sermorelin, Tesamorelin, and the broader GHRP class. This prohibition applies both in-competition and out-of-competition for all athletes subject to WADA testing. A positive test constitutes a full WADA anti-doping rule violation regardless of source, dose, or therapeutic rationale. There is no TUE pathway for CJC-1295.
Compounding context
Because there is no current approved drug product and no established USP monograph for CJC-1295, compounding it for clinical use sits in a tenuous regulatory position. The July 2026 FDA compounding reclassification review covers peptides in this category. If CJC-1295 is moved to the restricted list (alongside Sermorelin and the GHRPs), access through 503A/503B pharmacies may be eliminated.
What this means practically: CJC-1295 purchased outside FDA-approved channels is an unregulated compound. There is no manufacturer accountability and no guarantee of purity, identity, or dosing accuracy without independent lab testing. The regulatory environment is active and may change in the near term.
CJC-1295's regulatory framing changes month to month — never-approved status, WADA S2 GHRF-class retention, FTC telehealth enforcement against peptide blends containing CJC-1295, and the July 2026 FDA compounding review. The dated Regulatory Updates Log tracks the primary-source documents as they're published.
View CJC-1295 / GHRF regulatory entries →CJC-1295 vs. Sermorelin, Ipamorelin, and Tesamorelin
CJC-1295 is regularly stacked with Sermorelin and Ipamorelin (the "Sermorelin + Ipamorelin + CJC-1295" blend is the three-peptide expansion of the standard Sermon + Ipam wellness-clinic prescription) on the dual-axis GH-amplification rationale. The distinctions matter for understanding mechanism, dosing schedule, and regulatory exposure.
CJC-1295 (GHRF, long-acting): A 30-amino-acid modified GHRH analog with or without DAC (Drug Affinity Complex) serum-albumin binding. Binds the same GHRH receptor as Sermorelin with substantially extended plasma half-life (the DAC variant produces multi-day exposure). Same GHRH-receptor mechanism class — supported by the Walker 1994 pharmacodynamic data (PMID: 7527273) — but no published human efficacy RCTs for adult outcomes.
Sermorelin (GHRF, short-acting): A 29-amino-acid synthetic analog of GHRH 1–29, the same upstream receptor. Sermorelin's plasma half-life is measured in minutes, requiring nightly dosing. The Reutens 1996 and Walker 1994 pharmacodynamic programme is the shared mechanism-class anchor. Withdrawn from the US market in 2008 for commercial reasons; not FDA-approved for any current indication.
Ipamorelin (GHRP): Binds the ghrelin receptor (GHSR-1a) — a different receptor, a different step in the cascade than CJC-1295 or Sermorelin. Mechanistically distinct; pharmacologically complementary when stacked. No published human efficacy RCTs for adult endpoints. WADA S2 prohibited alongside CJC-1295.
All three are WADA S2 prohibited. None has human RCT data for body composition or anti-aging in healthy adults. Stacking all three amplifies GH release via two-axis stimulation (GHRH receptor + ghrelin receptor); it also stacks the regulatory violation, the unknown long-term safety profile in humans, and the buyer-side evidence gap. The three-way blend is the high-end peptide-clinic anti-aging prescription in 2026, but the underlying evidence for any specific adult endpoint remains absent on every component.
Compared to other GHRFs: Tesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy — the only GHRF in this category with a real approval — but its use is restricted to that single indication. CJC-1295 has no parallel exemption. Tesamorelin's approval trail is the closest analogue in the GHRF class, and it covered a narrow patient population with a specific clinical context (lipodystrophy in HIV patients on antiretroviral therapy), not the body-composition or longevity indications driving current wellness-clinic interest in either Tesamorelin or CJC-1295.
The Honest Verdict
CJC-1295 shares the GHRH-receptor mechanism class with Sermorelin (Walker 1994, PMID: 7527273); the half-life distinction is pharmacokinetic only. The upstream GHRH-receptor binding is established via Sermorelin's anchor pharmacodynamic work. The DAC variant's serum-albumin binding is a real pharmacokinetic property producing multi-day plasma exposure. The peptide is correctly characterized as a long-acting GHRH analog; this is a real mechanistic claim.
The DAC variant's extended exposure may produce more sustained GH-pulse amplification in adults. If preserved GH pulse amplification is sustained over multi-day intervals in healthy adults, downstream anabolic effects via IGF-1 are mechanistically expected. This is reasonable mechanistic reasoning from the Sermorelin anchor and the DAC pharmacokinetic extension — not clinical evidence. The size, duration, and frequency of GH-pulse amplification from CJC-1295 in real-world adult use has not been systematically characterized.
Body composition, anti-aging, recovery acceleration, and sleep quality improvements in healthy adults remain undemonstrated in human trials. The ConjuChem programme generated narrow pharmacokinetic/pharmacodynamic data. The online wellness-clinic ecosystem has retrofitted CJC-1295 into adult longevity protocols that have never been tested in humans. Mechanism and animal data are not clinical proof. Half-life extension is not efficacy extension.
WADA S2 prohibition is current and explicit. Any athlete subject to WADA testing faces a potential violation. CJC-1295 is not FDA-approved and has never been, and the FDA compounding status for GHRFs is in regulatory flux as of mid-2026. This is not a stable environment — access and legal status may shift in the near term.
CJC-1295 is a pharmacologically interesting GHRF with a documented half-life-extension advantage over Sermorelin and a real (if borrowed) upstream GHRH-receptor mechanism. It is not a proven therapy for any of the body composition, anti-aging, or recovery outcomes driving its current online popularity. The gap between the DAC's convenient weekly dosing schedule and demonstrable clinical efficacy for any specific adult endpoint is not a technicality — it's the absence of the controlled-trial evidence that would justify confidence.
References
- Reutens AT, et al. "GHRH 1-29 (Sermorelin) in the diagnostic evaluation of GH-deficient children." Clin Endocrinol (Oxf). 1996;44(2):137–146. PMID: 8834260 — background-reference; pediatric GH-deficiency diagnostic programme for the GHRH 1–29 mechanism class that CJC-1295 inherits.
- Walker BR, et al. "Sermorelin-induced GH pulsatility in healthy adults." J Clin Endocrinol Metab. 1994;79(6):1662–1667. PMID: 7527273 — the GHRH-receptor mechanism-class anchor; pharmacodynamic data underlying the CJC-1295 receptor targeting.
- WADA Prohibited List 2026 — S2 Peptide Hormones, GH-Releasing Factors (GHRFs) subcategory (CJC-1295 explicitly listed alongside Sermorelin, Tesamorelin, and the GHRP class).
- FDA Compounding Regulatory Docket — July 2026 reclassification review of peptides (covers CJC-1295 and the broader GHRF class).
- Clinical pharmacokinetic class — the DAC (Drug Affinity Complex) serum-albumin-binding extension pharmacokinetically extends the Walker 1994 mechanism-class anchor to multi-day plasma exposure; no new PMID — references the same mechanism class with a substantially extended pharmacokinetic window.
Understand What You're Actually Evaluating
The Peptide Safety & Evidence Decoder Kit walks through how to read peptide research, identify vendor red flags, and assess regulatory status — the literacy framework for evaluating compounds like CJC-1295.
Get the Decoder Kit Get the Long-Form Guide — $37